Seth Meyers checks in on 'pharma bro' Martin Shkreli, finds he's just the tip of a price-gouging iceberg
Martin Shkreli, the widely despised former CEO of Turing Pharmaceuticals, infamous for raising the price of a life-saving drug by 5,000 percent, was called to testify before Congress last week. But instead of answering questions, Seth Meyers said on Tuesday's Late Night, "he spent the time doing what he does best: looking like a real slappable prick." Meyers illustrated his point with some footage of Shkreli invoking his Fifth Amendment right instead of answering even the most mundane questions.
As fun as it is to make fun of Shkreli, though, he's "not alone," Meyers said. "He's just doing what a lot of pharmaceutical companies already do, except he's being loud and conniving about it while they're being secretive and conniving about it." In fact, Shkreli is "just a convenient, deserving scapegoat" for the price-gouging of Americans by the drug industry, Meyers said, aided by Congress' decision to prevent the U.S. government from negotiating the price of drugs, like almost every other country does. Case in point, a company called Valeant bought two heart drugs just last year and immediately raised the price 525 percent and 212 percent, Meyers said, but "Valeant didn't cause nearly as much outrage as Shkreli did because they don't have a smug, irritating face; they have a soothing logo." Watch Meyers' "closer look" at Shkreli and the unsavory behavior he exposed below. Peter Weber
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Could Trump run for a third term?The Explainer Constitutional amendment limits US presidents to two terms, but Trump diehards claim there is a loophole
-
Political cartoons for November 28Cartoons Friday's political cartoons include economic diagnosis, climate distractions, and more
-
What does the fall in net migration mean for the UK?Today’s Big Question With Labour and the Tories trying to ‘claim credit’ for lower figures, the ‘underlying picture is far less clear-cut’
-
US mints final penny after 232-year runSpeed Read Production of the one-cent coin has ended
-
Warner Bros. explores sale amid Paramount bidsSpeed Read The media giant, home to HBO and DC Studios, has received interest from multiple buying parties
-
Gold tops $4K per ounce, signaling financial uneaseSpeed Read Investors are worried about President Donald Trump’s trade war
-
Electronic Arts to go private in record $55B dealspeed read The video game giant is behind ‘The Sims’ and ‘Madden NFL’
-
New York court tosses Trump's $500M fraud fineSpeed Read A divided appeals court threw out a hefty penalty against President Trump for fraudulently inflating his wealth
-
Trump said to seek government stake in IntelSpeed Read The president and Intel CEO Lip-Bu Tan reportedly discussed the proposal at a recent meeting
-
US to take 15% cut of AI chip sales to ChinaSpeed Read Nvidia and AMD will pay the Trump administration 15% of their revenue from selling artificial intelligence chips to China
-
NFL gets ESPN stake in deal with DisneySpeed Read The deal gives the NFL a 10% stake in Disney's ESPN sports empire and gives ESPN ownership of NFL Network
